At InterveXion we develop novel products for the treatment of addiction disorders. Since our founding in 2004, our team has been dedicated to providing therapeutic options for patients suffering from the debilitating effects of addiction. We occupy office and laboratory space in the BioVentures Building on the campus of the University of Arkansas for Medical Sciences (UAMS), from whom we licensed our lead technology.
Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine. IXT-m200 represents a unique approach in addiction medicine – rather than trying to identify and block sites of action of methamphetamine in the brain, we bind methamphetamine in the blood to decrease brain penetration. This approach underlies all our programs, and has been recognized by the National Institute on Drug Abuse (NIDA) in their strategic plan, and NIDA has provided significant funding for our development programs to date.
IXT-m200 has received US FDA Fast Track Designation, and demonstrated positive clinical data in a Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). We are now studying IXT-m200 in a Phase 2 study for methamphetamine overdose (Meth-OD) and are planning another Phase 2 study of IXT-m200 in people with methamphetamine use disorder. If successful, we plan to advance IXT-m200 into pivotal studies to potentially support registration.
Finally, InterveXion is also interested in identifying collaborations and licensing opportunities in the area of drug abuse and addiction to add to our pipeline in the future, and we encourage interested parties to contact us for such discussions.